Format

Send to

Choose Destination
Biomed Res Int. 2015;2015:365273. doi: 10.1155/2015/365273. Epub 2015 Oct 4.

miR-125b Suppresses Proliferation and Invasion by Targeting MCL1 in Gastric Cancer.

Author information

1
Cancer Research Institute, Key Laboratory of Cancer Cellular and Molecular Pathology of Hunan Provincial University, University of South China, Hengyang 421001, China ; Department of Pathology, Shaoyang Medical College, Shaoyang 422000, China.
2
Graduate Department, University of South China, Hengyang 421001, China.
3
Cancer Research Institute, Key Laboratory of Cancer Cellular and Molecular Pathology of Hunan Provincial University, University of South China, Hengyang 421001, China.
4
Department of Pathology, Shaoyang Medical College, Shaoyang 422000, China.

Abstract

Understanding the molecular mechanisms underlying gastric cancer progression contributes to the development of novel targeted therapies. In this study, we found that the expression levels of miR-125b were strongly downregulated in gastric cancer and associated with clinical stage and the presence of lymph node metastases. Additionally, miR-125b could independently predict OS and DFS in gastric cancer. We further found that upregulation of miR-125b inhibited the proliferation and metastasis of gastric cancer cells in vitro and in vivo. miR-125b elicits these responses by directly targeting MCL1 (myeloid cell leukemia 1), which results in a marked reduction in MCL1 expression. Transfection of miR-125b sensitizes gastric cancer cells to 5-FU-induced apoptosis. By understanding the function and molecular mechanisms of miR-125b in gastric cancer, we may learn that miR-125b has the therapeutic potential to suppress gastric cancer progression and increase drug sensitivity to gastric cancer.

PMID:
26504803
PMCID:
PMC4609369
DOI:
10.1155/2015/365273
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Hindawi Limited Icon for PubMed Central
Loading ...
Support Center